Business
MetaVia Reports First Quarter 2025 Financial Results and Provides Corporate Update
MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced financial results for the first quarter ended March 31, 2025, and provided a corporate strategic update.
About this update from Metavia Inc.
[{"type":"text","content":"Announced Positive Top-Line Phase 1 MAD Trial Results for DA-1726 in Obesity, Demonstrating Compelling Weight Loss and Best-in-Class Potential for Glucose Control, Waist Reduction and Tolerability","length":196,"tagName":"p","attribs":{}},{"type":"text","content":"Additional Cohorts Planned to Determine Maximum Tolerated Dose of DA-1726","length":73,"tagName":"p","attribs":{}},{"type":"text","content":"Successfully Completed a Private Placement Resulting in $10 Million in Gross Proceeds ","length":85,"tagName":"p","attribs":{}},{"type":"text","content":"$11.2 Million in Cash at End of First Quarter, With the Additional $10.0 Million From the Private Placement, is Expected to Fund the Company Into 2026","length":155,"tagName":"p","attribs":{}},{"type":"text","content":"CAMBRIDGE, Mass., May 14, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced financial results for the first quarter ended March 31, 2025, and provided a corporate strategic update.","length":290,"tagName":"p"},{"type":"image","alt":"MetaVia Logo (PRNewsfoto/MetaVia Inc.)","displaySize":"","headline":null,"caption":"MetaVia Logo (PRNewsfoto/MetaVia Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":77,"url":"https://media.zenfs.com/en/prnewswire.com/116597eda2a36d52628a741d23461740"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/oKeVzvlzHhGood7_jpA63w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTEzNjtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/116597eda2a36d52628a741d23461740","width":400,"height":77}},"href":"https://mma.prnewswire.com/media/2568660/MetaVia_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":""In the first quarter and beyond, we achieved significant progress advancing the clinical development of our two next-generation cardiometabolic assets, highlighted by the positive results from Part 2 of the multiple ascending dose (MAD) Phase 1 trial of DA-1726, a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) for the treatment of obesity," stated Hyung Heon Kim, President and Chief Executive Officer of MetaVia. "We are now well capitalized into 2026 after a successful private ...